Kura Oncology (NASDAQ:KURA) Posts Earnings Results, Beats Expectations By $0.04 EPS

Kura Oncology (NASDAQ:KURA) announced its quarterly earnings data on Tuesday. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.04, FiscalAI reports. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $22.84 million for the quarter, compared to analyst estimates of $24.94 million.

Kura Oncology Stock Performance

Shares of Kura Oncology stock remained flat at $7.57 on Tuesday. The stock had a trading volume of 2,428,787 shares, compared to its average volume of 1,719,776. The firm has a market cap of $673.43 million, a P/E ratio of -2.25 and a beta of 0.56. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. Kura Oncology has a one year low of $6.75 and a one year high of $13.90. The firm’s 50 day moving average is $10.60 and its 200-day moving average is $9.79.

Insiders Place Their Bets

In other news, CEO Troy Wilson bought 100,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were acquired at an average cost of $11.12 per share, for a total transaction of $1,112,000.00. Following the completion of the acquisition, the chief executive officer owned 379,194 shares in the company, valued at approximately $4,216,637.28. This represents a 35.82% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Teresa Bair sold 31,487 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $12.63, for a total transaction of $397,680.81. Following the transaction, the insider owned 195,444 shares in the company, valued at approximately $2,468,457.72. The trade was a 13.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 153,881 shares of company stock valued at $1,708,183 in the last ninety days. 7.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on KURA shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, October 14th. Wedbush boosted their price target on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Barclays set a $24.00 price objective on shares of Kura Oncology in a research note on Wednesday, October 14th. Finally, Citigroup restated a “market outperform” rating on shares of Kura Oncology in a report on Wednesday, October 14th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus target price of $25.35.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.